The aim of this proposal is to assess the efficacy of prolonged treatment with low dose warfarin in the secondary prevention of venous thromboembolism (VTE) among patients with and without factor V Leiden mutation, a common inherited defect of hemostasis associated with increased risk of recurrent thrombus formation. The investigators propose to conduct a randomized, double-blind, placebo-controlled, multi-center trial among 800 men and women age 40 or greater with a documented idiopathic venous thrombosis who have completed a standard course of anticoagulation therapy within the last two years. Enrollment will be targeted to ensure at least 300 patients with factor V Leiden are randomized. Patients will be randomized to usual care plus placebo or to usual care plus a three to four year regimen of low-dose warfarin (intended INR 1.5-2.0). After an initial titration period, double-blind INR assessment and dose adjustment will be performed for all patients every two months, with a weekly follow-up whenever a blinded dose adjustment greater than 1 mg is made, and on an as needed basis consistent with best clinical judgment. Trial endpoints will include recurrent VTE, major bleeding episodes, and all cause mortality in the total patient population and separately in those patients who have factor V Leiden. Both qualifying events and reported endpoints will be confirmed by detailed medical record review using standardized diagnostic criteria based upon venographic and doppler ultrasound data, ventilation- perfusion scans, and pulmonary angiography. The trial has sufficient power to discern whether prolonged anticoagulation with low dose warfarin will reduce rates of recurrent disease with low bleeding risks both for all patients enrolled and for the subgroup of those who carry factor V Leiden mutation. The potential clinical impact of this trial is broad since a positive finding would strongly support chronic anticoagulation among the 300,000 US patients hospitalized each year with venous thrombosis who are at risk for recurrent disease following cessation of standard outpatient anticoagulation and for whom there is no regimen currently proven to have an acceptable risk to benefit ratio to support long term prophylaxis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL057951-03
Application #
6184201
Study Section
Clinical Trials Review Committee (CLTR)
Program Officer
Rosenberg, Yves
Project Start
1998-09-11
Project End
2003-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
3
Fiscal Year
2000
Total Cost
$281,954
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Marcucci, M; Iorio, A; Douketis, J D et al. (2015) Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. J Thromb Haemost 13:775-81
Douketis, James; Tosetto, Alberto; Marcucci, Maura et al. (2011) Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ 342:d813
King, Cristi R; Deych, Elena; Milligan, Paul et al. (2010) Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 104:750-4
Douketis, James; Tosetto, Alberto; Marcucci, Maura et al. (2010) Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 153:523-31
Ferder, N S; Eby, C S; Deych, E et al. (2010) Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost 8:95-100
Zee, Robert Y L; Bubes, Vadim; Shrivastava, Sanjay et al. (2009) Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach. Clin Chim Acta 402:189-92
Cushman, M; Glynn, R J; Goldhaber, S Z et al. (2006) Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost 4:2199-203
Shrivastava, S; Ridker, P M; Glynn, R J et al. (2006) D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 4:1208-14
Miles, J S; Miletich, J P; Goldhaber, S Z et al. (2001) G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 37:215-8